YKL-40 (also called chitinase 3-like protein 1 (CHI3L1) and human cartilage glycoprotein 39 (HC gp39)) is a 40-kDa heparin-binding glycoprotein ([@CIT0018], [@CIT0012]) that is produced by a variety of normal cells and cancer cells ([@CIT0018], [@CIT0009], [@CIT0012]). YKL-40 is a growth and differentiation factor---particularly for cartilage cells, bone cells, and fibroblasts ([@CIT0010])---that protects against cell death ([@CIT0013]), and it plays a role in angiogenesis ([@CIT0023], [@CIT0005]) and fibrosis ([@CIT0014]). In cancer cells, the production of YKL-40 is stimulated by stress influences such as hypoxia and radiotherapy, and it probably has a role in cancer cell growth, survival, and proliferation ([@CIT0012]).

Expression of YKL-40 in sarcomas has previously been studied by immunohistochemistry in chondrosarcomas ([@CIT0002]), and improved standardization of the staining method using tissue microarray (TMA) has been used in breast and ovarian cancer tissue ([@CIT0020], [@CIT0008]), but little is known about the expression and prognostic role of YKL-40 in soft-tissue sarcomas (STSs). We therefore investigated the expression of YKL-40 in STS and atypical lipomatous tumors (ALTs) by immunohistochemistry and TMA, and the prognostic significance of the YKL-40 expression was determined.

Patients and methods {#ss1}
====================

Patients {#ss2}
--------

We included 49 patients aged 58 (4--89) years at diagnosis, 20 females and 29 males, with newly diagnosed STS (n = 40) or ALT (n = 9) of the trunk wall and limbs who had been diagnosed and treated surgically in the period of 2004--2005 at the Department of Orthopedics, Rigshospitalet, Copenhagen ([Table](#T1){ref-type="table"}). With the exception of the ALTs, we used the histological diagnosis from the original pathology reports. We also used the grading from the original pathologist's report, performed according to Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) ([@CIT0006]). During the years 2004--2005 and until 2013, ALT was classified as an STS (ALT/well-differentiated liposarcoma), but in the most recently published WHO tumor classification ALT of the trunk wall and limbs is no longer classified as an STS (Dei Tos and Pedeutour 2002, 2013). ALT of the trunk wall and limbs has no metastatic potential unless dedifferentiation occurs, but it is still considered a locally aggressive mesenchymal neoplasm (Dei Tos and Pedeutour 2013), so we did not exclude ALT from the present study.

###### 

Patient and tumor characteristics including immunohistochemical YKL-40 staining results in 49 soft-tissue tumors

  Factor                                  Grade   YKL-40                  
  --------------------------------------- ------- -------- ---- ---- ---- ----
  Sex                                                                     
   Male                                   29      8        11   9    23   6
   Female                                 20      6        3    12   18   2
  Age                                                                     
   Mean                                   58      --       --   --   --   --
   Range                                  4--89                           
  Site                                                                    
   Trunk wall                             7       2        2    3    5    2
   Upper extremity                        11      5        4    2    8    3
   Lower extremity                        31      7        8    15   28   3
  Depth                                                                   
   Subcutaneus                            10      7        1    2    5    5
   Deep-seated                            39      7        13   19   36   3
  Size, cm                                                                
   \< 5                                   15      3        6    6    15   0
   \> 5                                   34      11       8    15   26   8
  Malignancy grade (FNCLCC)                                               
   1                                      14      --       --   --   6    8
   2                                      14      --       --   --   14   0
   3                                      21      --       --   --   21   0
  Histological type                                                       
   Atypical lipomatous tumor              9       9        0    0    1    8
   Myxoid liposarcoma                     7       1        5    1    7    0
   Leiomyosarcom                          6       1        1    4    6    0
   Myxofibrosarcoma                       5       0        2    3    5    0
   Liposarcoma                            3       0        1    2    3    0
   Malignant fibrous histiocytoma         3       0        0    3    3    0
   Myogenic sarcoma                       3       1        1    1    3    0
   Malignant periferel nervesheet tumor   3       0        2    1    3    0
   Myxofibroblastic sarcoma               2       0        1    1    2    0
   Synovial sarcoma                       1       0        0    1    1    0
   Epithelioid sarcoma                    1       0        0    1    1    0
   Rhabdomyosarcoma                       1       0        0    1    1    0
   Primitive neuroectodermal tumor        1       1        0    0    1    0
   Fibrosarcoma                           1       1        0    0    1    0
   Unclassifiable                         3       0        1    2    3    0
  Patients developing metastases          23      2        6    15   23   0
  Survival                                                                
   Alive                                  25      12       6    7    17   8
   Dead                                   24      2        8    14   24   0
  Total                                   49      14       14   21   41   8

The patients included constituted a cohort that could be followed retrospectively for a minimum of 5 years, or until death. In our pathology database 118 patients were identified, and of these 69 were excluded, 45 because they had previously been diagnosed with STS (or ALT) and had presented with a local recurrence (n = 36) or metastatic lesion (n = 9) in 2004--2005. The tumor tissue samples from the patients included had to be large enough to allow performance of TMA analysis, and 18 patients were excluded because (1) not enough tumor tissue was stored due to the surgery performed at our department being a re-excision after primary surgery elsewhere (n = 9), (2) only biopsy material was stored (n = 6), or (3) the primary tumor removed was very small (n = 3). Finally, 5 patients were excluded due to lack of follow-up, and 1 patient was excluded because the tumor was finally diagnosed as a bone sarcoma. Thus, 49 tumors remained for analysis.

Tissue and preparation of the TMA blocks {#ss3}
----------------------------------------

TMA paraffin blocks were prepared and stained in a standardized manner similar to that described previously for ovarian carcinomas ([@CIT0008]). After evaluation of all available sections, 1 representative area from a chosen section was marked by a pathologist, and 2 tissue cylinders of 2.0 mm were punched out from this area in each tumor block. These were transferred along with the other cylinders to a recipient paraffin block, the TMA block, and the biopsies were aligned and marked for identification. 98 biopsies were obtained, 2 from each tumor. Synovial tissue, which is known to be positive for YKL-40, was used as a positive control. The stability of the staining results has previously been checked using TMAs and regular tumor sections ([@CIT0008]). At the time of diagnosis, the sarcomas had been classified according to the WHO histological classification of soft-tissue tumors and histological grading was performed using the FNCLCC grading system ([@CIT0025]). The 49 tumors consisted of ALTs and 14 different histological subtypes of STS (Table).

YKL-40 staining {#ss4}
---------------

The staining procedure has been described previously in detail ([@CIT0019], [@CIT0008]).

![Immunohistochemical analysis of YKL-40 protein expression in paraffin sections of different types of soft-tissue sarcomas. The cytoplasmatic glycoproteins in both the tumor cells and the tumor stroma cells take up the stain, and it is therefore the intensity of all parts of the tumor that is evaluated. Positive immunostaining appears as a cytoplasmic, granular brown-colored staining. Left panel: a peripheral nerve sheet tumor, Trojani grade 2, with an average YKL-40 intensity score of 1. Middle panel: an unclassifiable sarcoma, Trojani grade 3, with an average YKL-40 intensity score of 2. Right panel: a synovial sarcoma, Trojani grade 3, with an average YKL-40 intensity score of 3.](ORT-85-195-g001){#F1}

Estimation of staining intensity {#ss5}
--------------------------------

The slides were evaluated independently by 2 investigators (MLH and LHC), and they were scored in a semiquantitative manner as: negative for YKL-40 (0 = no staining) or positive for YKL-40 (staining intensity graded as: 1 = weak, 2 = moderate, and 3 = high). The final score of the YKL-40 staining in each patient was calculated as the average value of the scores given by the 2 investigators. Thus, an average staining intensity (ASI) score of 0 was considered to be negative for YKL-40, while an ASI score of 0.5-1 was considered weakly positive, an ASI score of 2.5-1 moderately positive and an ASI score of 2.5-3 highly positive for YKL-40. Two tumors were each missing in one of the TMA sections. Remaining tissue sections from each of these were then stained individually, and evaluation of the reactivity and staining intensity, which was used for the statistical analysis, was performed on these. The evaluation of the reactivity and staining intensity was then performed on the remaining section from each tumor and that score was used for the statistical analysis.

Statistics {#ss6}
----------

Data are presented as mean (range). For comparison of YKL-40 staining level between the 3 histological malignancy grades, nonparametric analysis of variance for unpaired data (the Kruskal-Wallis test) and nonparametric testing for unpaired data (the Mann-Whitney U test) was used.

Survival data were extracted from the Danish Centralized Civil Register, and these were not disease-specific data but rather overall survival data (until death from any cause). Patient survival was analyzed using the Kaplan-Meier method and the influence of YKL-40 staining intensity and the histological malignancy grade on survival was evaluated, with calculation of the 95% confidence interval (CI) for the mean survival rate.

The study was approved by the Ethics Committee of the Capital Region of Denmark (HD-2007-075).

Results {#ss7}
=======

8 tumors were negative for YKL-40 staining and 41 were positive with weak (n = 4), moderate (n = 16), or high (n = 21) staining intensity (Table). 25 patients (with a mean follow-up of 6 (5--7) years) were still alive and 24 (with a mean follow-up of 2 (0.5--4) years) had died by the end of the follow-up period, and of the patients who died, 19 had developed metastatic disease. The mean ASI YKL-40 score was higher in tumor biopsies from patients who died (2.4) than in those from patients who were alive (1.5) at the end of the follow-up period (p = 0.01).

The YKL-40 staining intensity was different in the different histological grades of malignancy (p = 0.004) with higher values in the highly malignant tumors (grades 2 and 3) than in the low-malignancy tumors (grade 1). Similar ASI YKL-40 scores was found between groups, when the material was divided into groups with tumor size below 5 cm (n = 15) or above 5 cm (n = 34). Deep-seated tumors (n = 39) had an ASI YKL-40 score of 2.1, as compared to 1.2 in tumors with a subcutaneous location (p = 0.04).

The probability of 5-year survival of the whole group of patients (n = 49) was 51% ([Figure 2a](#F2){ref-type="fig"}). When the material was divided into 3 groups with (1) negative-staining or low ASI YKL-40 staining tumors (n = 12), (2) moderate staining-intensity tumors (n = 16), and (3) high staining-intensity tumors (n = 21), the mean survival rate was higher in the group with negative-staining or low staining-intensity tumors (6.4 years, CI: 5.5--7.3) than in the groups with moderate staining-intensity tumors (3.8 years, CI: 2.3--5.1) or high staining-intensity tumors (3.8 years, CI: 2.8--4.9) ([Figure 2b](#F2){ref-type="fig"}).

![Kaplan-Meier survival analysis. A. Survival analysis of all 49 patients with atypical lipomatous tumor (n = 9) or soft-tissue sarcoma (n = 40). B. Survival analysis of the 49 patients with atypical lipomatous tumor or soft-tissue sarcoma divided into 3 subgroups with negative or low ASI YKL-40 staining-intensity tumors (n = 12) (blue line), moderate staining-intensity tumors (n = 16) (brown line), and high staining-intensity tumors (n = 21) (green line). C. Survival analysis of the 49 patients with atypical lipomatous tumor or soft-tissue sarcoma divided into 3 subgroups based on the histological malignancy grade: grade-1 tumors (n = 14, blue line), grade-2 tumors (n = 14, green line), and grade-3 tumors (n = 21, brown line).](ORT-85-195-g002){#F2}

The histological grade of malignancy also influenced the probability of mean survival with grade-1 tumors (n = 14, mean survival rate 6.2 years, CI: 5.2--7.3) and grade-3 tumors (n = 21, mean survival rate 3.4 years, CI: 2.2--4.6) having significantly different mean survival rates. The mean survival rate for grade-2 tumors (n = 14, mean survival rate 4.2 years, CI: 3.1--5.4) was not significantly different to those for grade-1 and grade-3 tumors ([Figure 2c](#F2){ref-type="fig"}).

Discussion {#ss8}
==========

To our knowledge, this is the first report on YKL-40 expression in STS and ALT. We found that 41 of the tumors were positive for YKL-40. Only 8 tumors were negative for YKL-40. All 8 of these negative tumors were an ALT. The only ALT that was positive for YKL-40 had an osteochondroid dedifferentiation. A study on the expression of YKL-40 in chondroid tumors has shown a universal immunoreactivity for YKL-40 in chondrosarcomas ([@CIT0002]). The osteochondroid dedifferentiation of the ALT might explain the immunoreactivity to YKL-40. YKL-40 is associated with cancer aggressiveness, and it might be a predictor of a more malignant transformation of cancer cells ([@CIT0001]), which might explain why the ALT did not express YKL-40 at all.

The probability of 5-year survival for the whole group was 51%. The ASI YKL-40 score was higher in tumors from patients who had died during the follow-up period than in tumors from the patients who survived. When divided into subgroups according to the ASI score, the mean survival rate was higher in the group with staining-negative or low-intensity stained tumors. This suggests that YKL-40 expression in STS might be used as a prognostic factor for survival. This study is, however, too small to provide solid evidence, but our finding is similar to the results of other studies of YKL-40 expression in other tumors: glioblastomas ([@CIT0016]), epithelial ovarian cancer ([@CIT0026]), and gastric cancer ([@CIT0001]) with an association between YKL-40 expression and shorter survival. Other studies have established that tumor expression of YKL-40 is related to stage and histology, but has no correlation to overall survival ([@CIT0020], [@CIT0008], [@CIT0023]). The histological malignancy grade showed the same pattern as the ASI YKL-40 score on survival, with longer mean survival of patients with grade-1 tumors (including ALT) than of patients with grade-3 tumors. This correlates with the ASI YKL-40 score, which was higher in grade-3 tumors than in grade-1 tumors.

The ASI YKL-40 score was similar for tumors with size below 5 cm or larger than 5 cm, and between subcutaneous and deep-seated tumors. Tumor size along with histological type and grade is normally considered to be a prognostic factor ([@CIT0024], [@CIT0015], [@CIT0017]). A study of 490 STSs showed that depth had no major effect on survival when tumor grade and size were taken into account ([@CIT0021]). We had to exclude 18 patients due to having too little tissue; this may have biased our results regarding size and survival. A study by [@CIT0007] showed that size is of no prognostic value in liposarcomas (including ALT). The present study had 19 lipomatous tumors of various types (ALT, liposarcomas and myxiod liposarcomas), all of which were greater than 5 cm. 19 tumors of 49 is a large proportion, which may have influenced the association between ASI YKL-40 score and size.

YKL-40 concentration can be determined in serum by ELISA ([@CIT0011]) and it has been measured in more than 7,000 patients with different types of cancer. High serum YKL-40 is common in patients with bone, lung, and liver metastases ([@CIT0006], [@CIT0012]). Moreover, studies have shown that high serum YKL-40---compared to levels in healthy individuals---is an independent prognostic biomarker signaling short time to worsening of the disease and short time to death in patients with localized or disseminated cancer of the colon, breast, ovary, lung, prostate, kidney, skin, melanoma, blood cells, and bone marrow ([@CIT0022], [@CIT0012]). Several studies have shown that serum YKL-40 is useful for monitoring of recurrence and progression in cancer patients after surgery ([@CIT0009], [@CIT0012]).

The present study has shown that YKL-40 is expressed in STS, and in the future the degree of YKL-40 expression may be shown to be a clinically important prognostic marker of the severity of the disease. Degree of YKL-40 expression showed consistency with the FNCLCC grading, and survival in patients suffering from ALT/STS. However, in this study we could not determine whether YKL-40 expression is an independent prognostic factor that can add something new to the prognostic value of FNCLCC grading.

The YKL-40 expression that we found may contribute to the serum levels of YKL-40 in patients with STS and, if so, serum YKL-40 may have potential as a prognostic serum biomarker in STS patients. Further studies with a much larger sample size are warranted to determine whether YKL-40 expression (in a Cox proportional hazards regression analysis) still remains a significant prognostic factor, when analyzed together with the parameters that make up the FNCLCC grading system and perhaps even other parameters. Furthermore, the role of serum YKL-40 as a biomarker should be evaluated in larger prospective studies.
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